Semaglutide extends median lifespan 12% in aged female mice, Nature study finds
UC Berkeley team reports treated mice outperformed calorie-restricted controls on memory, movement and blood sugar, while NIH cautions the results do not translate to people.
PR
By Priya Raman · Science Reporter
Sep 18 08:50 ETSource: Medical Daily
The wire
- 01Female C57BL/6 mice treated with semaglutide from 20 months of age had median lifespan rise from 742 to 834 days, about 12 percent, in work published in Nature.
- 02Patients and sellers are already framing GLP-1s as longevity drugs; no human trial has tested semaglutide for aging and no regulator has approved that use.
- 03All animals were female and from a single inbred strain; the University of California has filed a patent application covering GLP-1 receptor agonists for healthy aging.
From the source
Read at medicaldaily.comSemaglutide Added About Three Months to the Lives of Old Female Mice and Human Longevity Claims Remain Unproven
Aged female mice given semaglutide late in life lived measurably longer than untreated animals, and the drug matched or exceeded the benefits of eating less on tests of memory, movement, and blood sugar control. Median lifespan rose from 742 days to 834 days, about 12 percent, according to the study published in Nature by a team at the University of California, Berkeley.